Business
AtriCure Announces the Launch of the cryoXT™ Device for Post-Operative Pain Management Following Amputation
New device expands AtriCure’s market opportunity in post-operative pain management while addressing a significant unmet clinical need MASON, Ohio--(BUSINESS
About this update from Atricure, Inc.
[{"type":"text","content":"\nNew device expands AtriCure’s market opportunity in post-operative pain management while addressing a significant unmet clinical need\n\n\n MASON, Ohio--(BUSINESS WIRE)--\nAtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced the launch of the cryoXT™ device, an innovative cryoablation technology used to help manage post-operative pain following amputation procedures.\n\n\nEach year, over 185,000 amputations occur in the U.S., with approximately 60%1 of patients experiencing residual limb pain and up to 85%2 reporting phantom limb pain. AtriCure’s cryoICE® platform uses a unique freezing method to block nerve pain signals. With the introduction of the cryoXT device, physicians now have access to a next-generation tool that brings this long-lasting approach to post-amputation pain management.\n\n\nRecently cleared under an FDA 510(k), the cryoXT device is designed to temporarily block pain following amputation by ablating peripheral nerves. As part of the cryoICE® platform, the cryoXT device builds on the proven safety and efficacy of AtriCure’s cryoSPHERE devices, which have been used in over 100,000 procedures since FDA clearance in November 2018. The device features a newly designed tip with multi-surface freezing technology to precisely target large diameter exposed peripheral nerves.\n\n\n“The launch of the cryoXT device reflects our commitment to bringing meaningful, differentiated solutions to patients and providers in a significant and underserved segment of the surgical market,” said Michael Carrel, President and CEO of AtriCure. “We’re addressing a clear gap in post-amputation care by helping more patients successfully manage pain. It’s a powerful combination of doing good and expanding AtriCure’s growth pathways.”\n\n\n“As an orthopedic surgeon, managing long-term pain after limb loss is a critical part of patient care,” said Dr. Bryan Houseman, DO, Orthopedic Surgeon at The Elliot Hospital in Manchester, NH. “The cryoXT device allows us to address pain at the time of surgery effectively, improving both recovery and quality of life, and represents a significant advancement in reducing post-surgical pain for our patients.”\n\n\n\nhttps://journals.lww.com/pain/abst...